Vivos Therapeutics (VVOS) Competitors $4.20 -0.40 (-8.70%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.22 +0.02 (+0.48%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS vs. NSPR, HYPR, OBIO, FONR, ZJYL, NVNO, APYX, BDMD, VANI, and TELAShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include InspireMD (NSPR), Hyperfine (HYPR), Orchestra BioMed (OBIO), Fonar (FONR), Jin Medical International (ZJYL), enVVeno Medical (NVNO), Apyx Medical (APYX), Baird Medical Investment (BDMD), Vivani Medical (VANI), and TELA Bio (TELA). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. Its Competitors InspireMD Hyperfine Orchestra BioMed Fonar Jin Medical International enVVeno Medical Apyx Medical Baird Medical Investment Vivani Medical TELA Bio InspireMD (NYSE:NSPR) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations. Which has stronger earnings & valuation, NSPR or VVOS? Vivos Therapeutics has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInspireMD$7.07M14.05-$19.92M-$0.83-2.87Vivos Therapeutics$15.03M2.10-$11.14M-$1.68-2.50 Do analysts prefer NSPR or VVOS? InspireMD presently has a consensus price target of $4.50, suggesting a potential upside of 89.08%. Vivos Therapeutics has a consensus price target of $4.82, suggesting a potential upside of 14.68%. Given InspireMD's stronger consensus rating and higher possible upside, equities analysts clearly believe InspireMD is more favorable than Vivos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Vivos Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media favor NSPR or VVOS? In the previous week, Vivos Therapeutics had 7 more articles in the media than InspireMD. MarketBeat recorded 7 mentions for Vivos Therapeutics and 0 mentions for InspireMD. InspireMD's average media sentiment score of 0.00 beat Vivos Therapeutics' score of -0.09 indicating that InspireMD is being referred to more favorably in the media. Company Overall Sentiment InspireMD Neutral Vivos Therapeutics Neutral Which has more volatility & risk, NSPR or VVOS? InspireMD has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.03, meaning that its stock price is 603% more volatile than the S&P 500. Do insiders and institutionals have more ownership in NSPR or VVOS? 44.8% of InspireMD shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 34.1% of InspireMD shares are held by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is NSPR or VVOS more profitable? Vivos Therapeutics has a net margin of -99.49% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets InspireMD-413.96% -69.42% -57.68% Vivos Therapeutics -99.49%-232.76%-84.30% SummaryInspireMD beats Vivos Therapeutics on 10 of the 16 factors compared between the two stocks. Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.52M$2.54B$5.83B$9.78BDividend YieldN/A1.67%4.40%4.05%P/E Ratio-2.5022.9031.3026.05Price / Sales2.10700.00454.60117.80Price / CashN/A179.1038.0259.36Price / Book6.895.939.536.60Net Income-$11.14M$31.83M$3.26B$265.65M7 Day Performance2.19%1.89%2.14%2.01%1 Month Performance-25.13%1.33%2.81%-0.33%1 Year Performance55.27%8.84%30.70%19.04% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics1.299 of 5 stars$4.20-8.7%$4.82+14.7%+59.1%$31.52M$15.03M-2.50160News CoverageEarnings ReportGap DownNSPRInspireMD3.5678 of 5 stars$2.41-3.2%$4.50+86.6%-16.5%$101.76M$7.07M-3.2550HYPRHyperfine1.7062 of 5 stars$1.28-1.2%$1.28+0.7%+22.2%$99.31M$12.89M-2.45190OBIOOrchestra BioMed3.1441 of 5 stars$2.56-2.9%$14.00+447.9%-58.7%$98.73M$2.64M-1.404Analyst ForecastFONRFonarN/A$15.16+0.4%N/A-11.0%$93.96M$102.88M12.12480ZJYLJin Medical InternationalN/A$0.60-2.4%N/A-79.4%$93.15M$23.50M0.00245News CoveragePositive NewsNVNOenVVeno Medical0.6727 of 5 stars$4.18-16.4%N/A-81.4%$80.36MN/A-3.4830Analyst DowngradeHigh Trading VolumeAPYXApyx Medical1.253 of 5 stars$1.98-7.5%N/A+60.8%$74.88M$48.10M-4.40270Gap DownBDMDBaird Medical InvestmentN/A$2.07-2.8%N/AN/A$73.96MN/A0.00N/AVANIVivani Medical2.4065 of 5 stars$1.22-1.6%$4.00+227.9%-8.1%$72.27MN/A-2.7120News CoverageTELATELA Bio2.9895 of 5 stars$1.75+2.6%$4.50+157.9%-38.5%$70.92M$69.30M-1.60120 Related Companies and Tools Related Companies InspireMD Competitors Hyperfine Competitors Orchestra BioMed Competitors Fonar Competitors Jin Medical International Competitors enVVeno Medical Competitors Apyx Medical Competitors Baird Medical Investment Competitors Vivani Medical Competitors TELA Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VVOS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access